Expression and Clinical Significance of IQGAP1 in Hepatocellular Carcinoma Tissues_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 LIChuan , CHENXiang ,  WENTian-fu

Department of Liver Surgery, West China Hospital of Sichuan University, Chengdu 610041, China;

Corresponding author：

WENTian-fu, Email: tianfu1962@163.com

Keywords：

Hepatocellular carcinoma; IQ motif-containing GTPase activating protein 1; Liver resection; Prognosis

DOI：

10.7507/1007-9424.20150314

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the expression of IQ motif-containing GTPase activating protein 1 (IQGAP1) in hepatocellular carcinoma (HCC) tissues, and to analyze the relationship of IQGAP1 and patient's clinical characteristics and prognosis after liver resection. Methods Data of 79 patients who received liver resection between 2007 and 2009 in our hospital were collected. The expression of IQGAP1 was examined by immunohistochemical tests. The clinical characteristics and prognosis were compared. Results IQGAP1 was detected in 43 patients (54.4%). Patients with IQGAP1 expression had more poor differentiation and microvascular invasion. The cumulative recurrence-free rate and overall survival rate in 1-, 3-, and 5-year after operation of patients with IQGAP1 expression (cumulative recurrencefree rate:67.4%, 39.5%, and 23.3%; cumulative overall survival rate:97.7%, 71.5%, and 53.3%) were poor than patients without IQGAP1 expression (cumulative recurrence-free rate:100%, 94.4%, and 83.3%; cumulative overall survival rate:1007%, 97.2%, and 88.9%), P < 0.001. Conclusions HCC patients with IQGAP1 expression had a poor prognosis after liver resection. IQGAP1 may be a prognostic indicator for hepatocellular carcinoma.

Citation： LIChuan, CHENXiang, WENTian-fu. Expression and Clinical Significance of IQGAP1 in Hepatocellular Carcinoma Tissues. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2015, 22(10): 1214-1217. doi: 10.7507/1007-9424.20150314 Copy

1.	Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol, 2008, 48 Suppl 1:S20-S37.
2.	Cabibbo G, Petta S, Maida M, et al. Sorafenib for hepatocellular carcinoma:from randomized controlled trials to clinical practice. Dig Dis, 2015, 33(5):668-674.
3.	Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet, 2012, 379(9822):1245-1255.
4.	Venook AP, Papandreou C, Furuse J, et al. The incidence and epidemiology of hepatocellular carcinoma:a global and regional perspective. Oncologist, 2010, 15 Suppl 4:5-13.
5.	Michielsen PP, Francque SM, van Dongen JL. Viral hepatitis and hepatocellular carcinoma. World J Surg Oncol, 2005, 3:27.
6.	Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55(2):74-108.
7.	Wang H, Yang J, Zhang X, et al. Liver resection in hepatitis B-related hepatocellular carcinoma:clinical outcomes and safety in overweight and obese patients. PLoS One, 2014, 9(6):e99281.
8.	Dan J, Zhang Y, Peng Z, et al. Postoperative neutrophil-tolymphocyte ratio change predicts survival of patients with small hepatocellular carcinoma undergoing radiofrequency ablation. PLoS One, 2013, 8(3):e58184.
9.	Li C, Wen TF, Yan LN, et al. Outcome of hepatocellular carcinoma treated by liver transplantation:comparison of living donor and deceased donor transplantation. Hepatobiliary Pancreat Dis Int, 2010, 9(4):366-369.
10.	Li C, Wen TF, Yan LN, et al. Scoring selection criteria including total tumour volume and pretransplant percentage of lymphocytes to predict recurrence of hepatocellular carcinoma after liver transplantation. PLoS One, 2013, 8(8):e72235.
11.	Briggs MW, Sacks DB. IQGAP proteins are integral components of cytoskeletal regulation. EMBO Rep, 2003, 4(6):571-574.
12.	White CD, Brown MD, Sacks DB. IQGAPs in cancer:a family of scaffold proteins underlying tumorigenesis. FEBS Lett, 2009, 583(12):1817-1824.
13.	Zhao H, Xie C, Lin X, et al. Coexpression of IQ-domain GTPaseactivating protein 1(IQGAP1) and Dishevelled (Dvl) is correlated with poor prognosis in non-small cell lung cancer. PLoS One, 2014, 9(12):e113713.
14.	Hayashi H, Nabeshima K, Aoki M, et al. Overexpression of IQGAP1 in advanced colorectal cancer correlates with poor prognosis-critical role in tumor invasion. Int J Cancer, 2010, 126(11):2563-2574.
15.	Tseng PC, Chen CL, Shan YS, et al. An increase in integrin-linked kinase non-canonically confers NF-kappaB-mediated growth advantages to gastric cancer cells by activating ERK1/2. Cell Commun Signal, 2014, 12:69.
16.	Wang XX, Li XZ, Zhai LQ, et al. Overexpression of IQGAP1 in human pancreatic cancer. Hepatobiliary Pancreat Dis Int, 2013, 12(5):540-545.
17.	Sumie S, Kuromatsu R, Okuda K, et al. Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol, 2008, 15(5):1375-1382.
18.	Lai Q, Merli M, Ginanni Corradini S, et al. Predictive factors of recurrence of hepatocellular carcinoma after liver transplantation:a multivariate analysis. Transplant Proc, 2009, 41(4):1306-1309.
19.	Liu Z, Liu D, Bojdani E, et al. IQGAP1 plays an important role in the invasiveness of thyroid cancer. Clin Cancer Res, 2010, 16(24):6009-6018.
20.	Kubo S, Tanaka H, Shuto T, et al. Clinicopathologic features and outcome after liver resection for hepatocellular carcinoma in patients with concurrent versus previous chronic hepatitis B. Surg Today, 2005, 35(3):216-222.
21.	Shah SA, Cleary SP, Wei AC, et al. Recurrence after liver resection for hepatocellular carcinoma:risk factors, treatment, and outcomes. Surgery, 2007, 141(3):330-339.
22.	Zheng SS, Xu X, Wu J, et al. Liver transplantation for hepatocellular carcinoma:Hangzhou experiences. Transplantation, 2008, 85(12):1726-1732.
23.	DuBay D, Sandroussi C, Sandhu L, et al. Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg, 2011, 253(1):166-172.
24.	Briggs MW, Li Z, Sacks DB. IQGAP1-mediated stimulation of transcriptional co-activation by beta-catenin is modulated by calmodulin. J Biol Chem, 2002, 277(9):7453-7465.
25.	Meng D, Wu W, Li Z, et al. IQGAP1 modulates the proliferation and invasion of thyroid cancer cells in response to estrogen. Int J Mol Med, 2015, 36(2):588-594.

1. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol, 2008, 48 Suppl 1:S20-S37.
2. Cabibbo G, Petta S, Maida M, et al. Sorafenib for hepatocellular carcinoma:from randomized controlled trials to clinical practice. Dig Dis, 2015, 33(5):668-674.
3. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet, 2012, 379(9822):1245-1255.
4. Venook AP, Papandreou C, Furuse J, et al. The incidence and epidemiology of hepatocellular carcinoma:a global and regional perspective. Oncologist, 2010, 15 Suppl 4:5-13.
5. Michielsen PP, Francque SM, van Dongen JL. Viral hepatitis and hepatocellular carcinoma. World J Surg Oncol, 2005, 3:27.
6. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55(2):74-108.
7. Wang H, Yang J, Zhang X, et al. Liver resection in hepatitis B-related hepatocellular carcinoma:clinical outcomes and safety in overweight and obese patients. PLoS One, 2014, 9(6):e99281.
8. Dan J, Zhang Y, Peng Z, et al. Postoperative neutrophil-tolymphocyte ratio change predicts survival of patients with small hepatocellular carcinoma undergoing radiofrequency ablation. PLoS One, 2013, 8(3):e58184.
9. Li C, Wen TF, Yan LN, et al. Outcome of hepatocellular carcinoma treated by liver transplantation:comparison of living donor and deceased donor transplantation. Hepatobiliary Pancreat Dis Int, 2010, 9(4):366-369.
10. Li C, Wen TF, Yan LN, et al. Scoring selection criteria including total tumour volume and pretransplant percentage of lymphocytes to predict recurrence of hepatocellular carcinoma after liver transplantation. PLoS One, 2013, 8(8):e72235.
11. Briggs MW, Sacks DB. IQGAP proteins are integral components of cytoskeletal regulation. EMBO Rep, 2003, 4(6):571-574.
12. White CD, Brown MD, Sacks DB. IQGAPs in cancer:a family of scaffold proteins underlying tumorigenesis. FEBS Lett, 2009, 583(12):1817-1824.
13. Zhao H, Xie C, Lin X, et al. Coexpression of IQ-domain GTPaseactivating protein 1(IQGAP1) and Dishevelled (Dvl) is correlated with poor prognosis in non-small cell lung cancer. PLoS One, 2014, 9(12):e113713.
14. Hayashi H, Nabeshima K, Aoki M, et al. Overexpression of IQGAP1 in advanced colorectal cancer correlates with poor prognosis-critical role in tumor invasion. Int J Cancer, 2010, 126(11):2563-2574.
15. Tseng PC, Chen CL, Shan YS, et al. An increase in integrin-linked kinase non-canonically confers NF-kappaB-mediated growth advantages to gastric cancer cells by activating ERK1/2. Cell Commun Signal, 2014, 12:69.
16. Wang XX, Li XZ, Zhai LQ, et al. Overexpression of IQGAP1 in human pancreatic cancer. Hepatobiliary Pancreat Dis Int, 2013, 12(5):540-545.
17. Sumie S, Kuromatsu R, Okuda K, et al. Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol, 2008, 15(5):1375-1382.
18. Lai Q, Merli M, Ginanni Corradini S, et al. Predictive factors of recurrence of hepatocellular carcinoma after liver transplantation:a multivariate analysis. Transplant Proc, 2009, 41(4):1306-1309.
19. Liu Z, Liu D, Bojdani E, et al. IQGAP1 plays an important role in the invasiveness of thyroid cancer. Clin Cancer Res, 2010, 16(24):6009-6018.
20. Kubo S, Tanaka H, Shuto T, et al. Clinicopathologic features and outcome after liver resection for hepatocellular carcinoma in patients with concurrent versus previous chronic hepatitis B. Surg Today, 2005, 35(3):216-222.
21. Shah SA, Cleary SP, Wei AC, et al. Recurrence after liver resection for hepatocellular carcinoma:risk factors, treatment, and outcomes. Surgery, 2007, 141(3):330-339.
22. Zheng SS, Xu X, Wu J, et al. Liver transplantation for hepatocellular carcinoma:Hangzhou experiences. Transplantation, 2008, 85(12):1726-1732.
23. DuBay D, Sandroussi C, Sandhu L, et al. Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg, 2011, 253(1):166-172.
24. Briggs MW, Li Z, Sacks DB. IQGAP1-mediated stimulation of transcriptional co-activation by beta-catenin is modulated by calmodulin. J Biol Chem, 2002, 277(9):7453-7465.
25. Meng D, Wu W, Li Z, et al. IQGAP1 modulates the proliferation and invasion of thyroid cancer cells in response to estrogen. Int J Mol Med, 2015, 36(2):588-594.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Expression and Clinical Significance of IQGAP1 in Hepatocellular Carcinoma Tissues

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content